Engineered immune cells take on Hard-to-Treat myeloma
NCT ID NCT04795882
First seen Nov 20, 2025 · Last updated Jun 22, 2026 · Updated 21 times
Summary
This early-stage trial is testing two types of CAR T cell therapies for people with multiple myeloma that has come back or not responded to standard treatments. The therapies use a patient's own immune cells, modified to target the BCMA protein (alone or together with CD19) on cancer cells. The study aims to see if these cells can be made safely and whether they cause serious side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University College London Hospital
RECRUITINGLondon, County (Optional), United Kingdom
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
BCMA CAR T cells and BCMA/CD19 CAR T cells
What this could lead to
If successful, this could point toward a new treatment option for patients with multiple myeloma that has not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 27 participants, so it is primarily testing safety and manufacturing feasibility. The treatment may not work or could cause severe side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.